Trial Profile

A Phase I/II Multi-center Study of HDM201 Added to Chemotherapy in Adult Subjects With Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siremadlin (Primary) ; Anthracyclines; Cytarabine; Cytarabine/daunorubicin; Daunorubicin; Idarubicin; Midazolam; Midostaurin; Posaconazole
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

30 Jul 2022 This trial has been Discontinued in Germany and Italy, according to European Clinical Trials Database record.
06 Jan 2020 Status changed from recruiting to withdrawn prior to enrolment.
03 Oct 2019 Planned End Date changed from 18 Apr 2023 to 13 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com